ClinicalTrials.gg
RecruitingNCT07292688Updated Jan 23, 2026

Study of CM383 in Healthy Subjects

A Phase 1 interventional study of CM383 and CM383 in Healthy, sponsored by Keymed Biosciences Co.Ltd. Recruiting at 1 site in China. Open to male participants aged 18 Years to 54 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by Keymed Biosciences Co.Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 54 Years
Sex
Male
01

Study summary

This study is a Phase I, single-center, randomized, open-label, parallel-controlled study, aimed at evaluating the pharmacokinetics, pharmacodynamics, immunogenicity, safety, and tolerability of a single dose of CM383 administered via intravenous infusion or subcutaneous injection in healthy male subjects.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Keymed Biosciences Co.Ltd is the lead sponsor of 68 studies on the registry; 34 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 54 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects age ≥ 18 years \& ≤54 years.
  • Subjects voluntarily signed the Form and were able to comply with the provisions of this protocol.

Exclusion criteria

Exclusion Criteria:

  • The average number of cigarettes smoked per day is greater than 5 within 3 months prior to screening.
  • Drinking heavily within 3 months prior to screening, or unable to guarantee not to drink alcohol during the research period, or positive alcohol breath testing.
  • History of drug abuse within 1 year prior to screening, or positive urine drug abuse screening.
  • Blood donation or any other form of blood loss exceeding 400 mL, or accepting blood transfusion within 12 weeks prior to screening.
  • Suspected allergy to Aβ-antibody drugs, humanized monoclonal antibody drugs and their , or other biological agents, or have a history of severe allergic reactions to other drugs.
  • Severe trauma or undergo major surgery within 6 months prior to screening, or planned surgery during the research period.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    CM383 subcutaneous injection group 1

    Biological: CM383

  • Experimental
    CM383 subcutaneous injection group 2

    Biological: CM383

  • Experimental
    CM383 intravenous infusion group

    Biological: CM383

Interventions

  • BiologicalCM383

    CM383 subcutaneous injection, once.

  • BiologicalCM383

    CM383 intravenous infusion, once.

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic characteristics of a single-dose administration of CM383 in healthy male subjects

    Pharmacokinetic concentrations in serum and pharmacokinetic parameters: maximum concentration (Cmax).

    Time frame: Up to Day 85

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2026; primary completion for Jul 2026, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2025
First posted
Dec 18, 2025
StartEst.
Jan 2026
Primary completionEst.
Jul 2026
CompletionEst.
Jul 2026
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07292688
Responsible party
Sponsor
First posted
Dec 18, 2025
Start date
Jan 2026 (estimated)
Primary completion
Jul 2026 (estimated)
Completion
Jul 2026 (estimated)
Last update
Jan 23, 2026

Study contacts

Qian Jia
Contact
qianjia@keymedbio.com
028-88610620
Bo Jiang
principal investigator · Second Affiliated Hospital, School of Medicine, Zhejiang University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion